Novo Nordisk's Mixed August: A Failed Heart Study, a Dutch Court Win, and a Bet on AI
Published on 08/20/2026 at 18:11 | Redaktion boerse-global.de
Novo Nordisk's shares have spent much of 2025 drifting sideways, and the latest stretch of news does little to change that picture. The Danish drugmaker closed at €39.78 on a recent Wednesday, up 0.7% on the day, yet the stock remains mired in negative territory over nearly every meaningful timeframe. The 30-day decline stands at 8.5%, while the year-to-date loss has widened to 9.6%. From the January peak of €54.86, the shares are now roughly 27% lower, though they sit about 32% above the early-March trough — a middling position within the 52-week range.
The most consequential development landed in late July, when the company disclosed that its ZEUS trial had failed to hit its primary cardiovascular endpoint. The study tested ziltivekimab, an IL-6 pathway inhibitor, in patients with atherosclerotic cardiovascular disease, chronic kidney disease, and systemic inflammation. While the drug did lower inflammatory markers such as high-sensitivity CRP as expected, it produced no meaningful reduction in major adverse cardiovascular events compared with placebo — the hazard ratio came in at 0.99, effectively a null result.
Management insists the disappointment won't alter the previously issued guidance for 2026 adjusted operating profit. Still, the company will record a non-cash impairment charge in the third quarter of 2026, a reminder that late-stage failures carry a balance-sheet cost even when they don't move the full-year outlook.
Against that backdrop, the company has been leaning on other levers. A strategic alliance with Amazon Web Services, announced around the same period, positions AWS as Novo Nordisk's preferred cloud provider and AI partner. The two companies have opened a joint innovation hub in London, where engineers and scientists will work with AWS's AI tools and Novo Nordisk's proprietary data to compress the timeline from target identification to first human dose. The move signals a conviction that computational efficiency in R&D will be a competitive differentiator as the GLP-1 wars intensify.
On the legal front, the company has notched wins on two continents. A federal court in San Antonio dismissed an antitrust lawsuit brought by Strive Specialties in its entirety, per Reuters. In the Netherlands, a district court in The Hague issued a preliminary injunction against Ceban Ziekenhuisfarmacie B.V., ordering the Dutch firm to halt distribution of a compounded semaglutide nasal spray. The court found that Ceban had infringed Novo Nordisk's supplementary protection certificate covering semaglutide. Neither ruling carries immediate financial impact, but both bolster the company's defenses against the growing market for copycat and compounding products.
When a high-profile trial misses its mark, it's a reminder that managing risk properly matters in every industry — including your own workplace. Many employers overlook gaps in their health and safety documentation until it's too late. A free toolkit with 41 ready-to-use templates and checklists helps you document risks properly and stay compliant. Download the free Risk Assessment Toolkit
CEO Mike Doustdar, meanwhile, has pushed back on the narrative that the obesity-drug market is devolving into a winner-take-all contest between Novo Nordisk and Eli Lilly. In an interview covered by Reuters, he pointed to demand for differentiated offerings — the oral Wegovy formulation among them — and the breadth of the company's pipeline as evidence that the competitive picture is more nuanced than a two-horse race. The comments arrive as analysts grow increasingly wary of the competitive dynamics in the GLP-1 segment; Berenberg downgraded the stock from Buy to Hold roughly a week ago, cutting its price target to $47 on concerns about intensifying rivalry in the obesity space.
The company has also been steadily buying back its own shares. Between August 10 and 14, it repurchased one million B-shares at an average price of DKK 303.59. That brings the current buyback program's total to 14,125,000 shares, and cumulative repurchases since the program began on February 4 to 28,884,179 B-shares. August 14 also marked the ex-dividend date, with a payout of DKK 3.75 per share at the Copenhagen exchange — a routine calendar event rather than an operational signal.
The technical picture offers little clarity. The stock's relative strength index sits at 43.4, suggesting neutral-to-slightly-bearish momentum without flashing an oversold signal. At the most recent reading, the share price was 4.4% below its 50-day moving average.
While Novo Nordisk defends its pipeline, you can protect your own operations from costly compliance failures. Over 37,000 UK businesses already rely on a free health and safety toolkit covering everything from fire safety to COSHH and first aid. Get the free Health & Safety Toolkit
Taken together, the recent stretch paints a portrait of a company working multiple fronts simultaneously: defending its intellectual property in court, modernizing its research engine through cloud and AI partnerships, and buying back stock even as its shares languish. The ZEUS failure, however, underscores the inherent risk in the pipeline that management hopes these other efforts will mitigate. For investors, the question is whether the sum of these parts — legal shields, technological investment, and capital returns — can offset the reality of a high-profile clinical miss and an increasingly crowded market.
